Feds put Teva's Copaxone, Azilect marketing under FCA microscope

Federal prosecutors are eyeing Teva Pharmaceutical Industries ($TEVA) for potential marketing violations. As Bloomberg reports, the Justice Department has demanded documents related to Teva's marketing of its multiple sclerosis drug Copaxone and its Parkinson's disease treatment Azilect. The government is investigating "potential violations of the False Claims Act," the company said in its annual filing with the Securities and Exchange Commission. Report